 Vaccine against Gram-negative bacterial infections |
| OF THE PREFERRED EMBODIMENTS According to the present invention, a non-covalent, polyvalent ... |
|
| Inhibitor of stem cell proliferation and uses thereof |
| The present invention relates to polypeptides which are inhibitors of stem cell proliferation ("INPR... |
|
| Inhibitor of stem cell proliferation and uses thereof |
| The present invention relates to an inhibitor of stem cell proliferation (INPROL) characterized by ... |
|
| Method of inhibiting angiogenesis using secreted proteins |
| Isolated Proteins Nucleotide and amino acid sequences, as presently determined, are reported below ... |
|
| Balanced extraction system |
| The present invention is a device wherein matter to be extracted which contains various available ... |
|
| Compounds for the treatment of hepatoma |
| What is claimed is: 1. The method of treatment of a living subject affected by hepatoma which ... |
|
| 5ht2 agonists for controlling IOP and treating glaucoma |
| 1. A method for lowering or controlling intraocular pressure or treating glaucoma which comprises ... |
|
| Insect resistant tomato and potato plants |
| We claim: 1. A chimeric gene capable of expressing in a plant cell comprising in sequence: (a) a ... |
|
| Insect resistant plants |
| In accordance with one aspect of the present invention, there has been provided a method for ... |
|
|
Amyloid .beta. protein (globular assembly and uses thereof)
| Details |
Inventors: Krafft, Grant A.; Klein, William L.; Chromy, Brett A.; Lambert, Mary P.; Finch, Caleb E.; Morgan, Todd; Wals, Pat; Rozovsky, Irina; Barlow, Ann;
Assignee: Northwestern University (Evanston, IL); University of Southern California (Los Angeles, CA)
Primary Examiner: Low; Christopher S. F.
Assistant Examiner: Gupta; Anish
Attorney, Agent or Firm: McDonnell, Boehnen, Hulbert & Berghoff
The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid .beta. peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs. |
|
DETAILED DESCRIPTION What is claimed is: 1.
An isolated, soluble, non-fibrillar amyloid .
beta.
protein assembly comprising 3-12 amyloid .
beta.
proteins, wherein the amyloid .
beta.
protein is the .
beta.
1-42 protein and wherein the assembly has neurotoxicity.
2.
The amyloid .
beta.
protein assembly according to claim 1 wherein said protein assembly has a molecular weight of about 27 kD to about 28 kD as measured by non-denaturing gel electrophoresis.
3.
The amyloid .
beta.
protein assembly according to claim 1 wherein said protein assembly has a molecular weight of about 23 kD to about 24 kD as measured by non-denaturing gel electrophoresis.
4.
The amyloid .
beta.
protein assembly according to claim 1 wherein said protein assembly comprises globules with dimensions of about 4.
9 nm to about 5.
3 nm as measured by atomic force microscopy.
5.
The amyloid .
beta.
protein assembly according to claim 1 wherein said protein assembly comprises globules with dimensions of about 5.
7 nm to about 6.
2 nm as measured by atomic force microscopy.
6.
The amyloid .
beta.
protein assembly according to claim 1 wherein about 70% of said protein assembly comprises a mixture of globules with dimensions of about 4.
9 nm to about 5.
3 nm and dimensions of about 5.
7 nm to about 6.
2 nm, wherein the dimensions are measured by atomic force microscopy.
7.
A method for assaying the effects of the amyloid .
beta.
protein assembly according to claim 1, comprising: (a) administering said protein assembly to the hippocampus of an animal; (b) applying an electrical stimulus; and (c) measuring the cell body spike amplitude over time to determine the long term potentiation response.
8.
The method of claim 7, wherein the long-term potentiations response of said animal is compared to the long-term potentiation response of another animal treated in the same fashion except having saline administered instead of protein assembly prior to application of the electrical stimulus.
Description:
BACKGROUND OF THE INVENTION 1.
Field of Invention This invention is related to amyloid
|
| Related patents |
|
|
Chlamydia antigens and corresponding DNA fragments and uses thereof
The present invention provides purified and isolated polynucleotide molecules that encode the Chlamydia polypeptide designated 76 kDa protein (SEQ ID No: 1) which can be ...
|
|
|
Methods of treating inflammatory bowel disease using cholera toxin B subunit
What is claimed is: 1. A method of treating inflammatory bowel disease in a subject diagnosed with inflammatory bowel disease, comprising administering to the subject a ...
|
|
|
Mammalian haemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof
1. Hemoglobin derivative compatible with human and non-human animal plasma, comprising hemoglobin crosslinked by means of a crosslinker for proteins and a polyalkylene ...
|
|
|
Anti hepatitis C virus antibody and uses thereof
OF THE PRESENT INVENTION Accordingly, the technical problem of the invention is to provide means and methods for the treatment and prevention of HCV infection in humans....
|
|
|
Chemical and/or biological decontamination system
OF THE INVENTION The present invention provides a composition that is effective in the decontamination of chemical agents and/or biological pathogens. The biological ...
|
|
|
Immunostimulant bacterial membrane fractions in cancer treatment
The invention claimed is: 1. A method of stimulating an immune response and/or inducing an antitumor immune response in a mammal, including a human, in need thereof, ...
|
|
|
Cloning and characterization of a human adenylyl cyclase
One aspect of the invention is an isolated and purified human type VI adenylyl cyclase (hAC6) polypeptide comprising the amino acid sequence of FIG. 1 (SEQ ID NO:2). A...
|
|
|
Tumor antigen based on products of the tumor suppressor gene WT1
What is claimed is: 1. An isolated polypeptide which consists of at most 12 contiguous amino acid residues of a human WT1 protein, wherein the polypeptide comprises SEQ I...
|
|
|
Methods of inhibiting GPR-9-6 function
The invention relates to an antibody (immunoglobulin) or functional fragment thereof (e.g., an antigen-binding fragment) which binds to a mammalian GPR-9-6 (GPR-9-6 is ...
|
|
|
Method for cloning of a rare, specifically mutated cell
The invention is a new and improved method for reliably detecting the presence of a rare cell having a desired nucleotide mutation that was introduced by a sequence-...
|
|
|
Drugs 
